findmyKOL

Timothy Henrich, MD

Enriched profile

Professor of Medicine, University of California, San Francisco · University of California, San Francisco

ORCIDNPI
Region🇺🇸 San Francisco, CA · West · United StatesSpecialtyInfectious DiseaseFocusHIV Research and Treatment+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2022–2025NIH funding2015–2026

Timothy Henrich is Professor of Medicine, University of California, San Francisco at University of California, San Francisco. OpenAlex indexes 236 publications with 11,074 citations (h-index 53); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 27 Aug 2026

Timothy Henrich, M.D., is Professor of Medicine, University of California, San Francisco. The public record shows 236 publications with 11,074 citations (h-index 53), centered on HIV Research and Treatment, Long-Term Effects of COVID-19, COVID-19 Clinical Research Studies. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 4 companies, 17 NIH-funded awards (2015–2026).

  • Most recent indexed publication: 2026 · International journal of molecular sciences
  • Top research focus: HIV Research and Treatment
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
HIV4 trialsCOVID-193 trialsHIV Infections1 trial

Research focus

OpenAlex concept fingerprint
HIV Research and TreatmentLong-Term Effects of COVID-19COVID-19 Clinical Research StudiesHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Drugs & molecules

across trials, industry payments and publications
Anktivageneric · Nogapendekin alfa inbakiceptClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
CellSight Technologies, Inc.Clinical trials2Industry paymentsRegeneron Pharmaceuticals, Inc.Clinical trialsIndustry payments2University of California, San FranciscoClinical trials2Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
236publications

Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.

11,074citations

Total citations across indexed works.

53h-index

Hirsch index (OpenAlex). i10-index 124.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
4companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
17NIH grants · 2015–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

4 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2020)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    47.4%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor21.2%
    Tivicay100%
    Part D<11 patients
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor17.5%
    Descovy100%
    Part D<11 patients
  • Cardiovascular

    24.8%
    Statin14.6%
    Atorvastatin Calcium100%
    Part D<11 patients
    Calcium channel blocker10.2%
    Amlodipine Besylate100%
    Part D<11 patients
  • Respiratory

    17.5%
    Corticosteroid8.8%
    Fluticasone Propionate100%
    Part D<11 patients
    beta2-Adrenergic Agonist8.8%
    Ventolin Hfa100%
    Part D<11 patients
1 more therapeutic area behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

17 NIH research awards on record, funded 20152026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Steven G. Deeks117Michael J. Peluso102Jeffrey N. Martin69

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/timothy-henrich-694b3111

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/Timothy-J-Henrich-15530967

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    polybio.org/interviews/polybios-dr-amy-proal-interviews-dr-tim-henrich-on-imaging-deep-tissue-sars-cov-2-reservoirs-in-longcovid

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →polybio.org
  • Other

    tlcsessions.net/episodes/episode-69-prof-tim-henrich-viral-persistence-and-t-cell-dysregulation

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcsessions.net
  • X / Twitter

    x.com/polybioRF/status/1989451996722852045

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.M.Sc.

    Harvard University School of Medicine

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • M.D.

    Yale University School of Medicine

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu
  • B.A.

    Oberlin College

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu

Editorial & leadership roles

journal and society appointments
  • Fellow

    Infectious Diseases Society of America (FIDSA)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →idsociety.org
  • Director

    UCSF CIDMI

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cidmi.ucsf.edu

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.